MILFORD, Mass., Apr 22, 2003 (BUSINESS WIRE) -- Waters Corporation (NYSE:WAT) reported today first quarter 2003 sales of $221 million, an increase of 10% over the $200 million in sales reported for the first quarter of 2002. This growth is comprised of 2% organic growth (prior to currency effects) and an 8% benefit from foreign exchange in the quarter. Earnings per diluted share (E.P.S.) for the first quarter were $0.26 compared to $0.26 for the comparable period in 2002. On a pro-forma basis, excluding unusual charges, E.P.S. were $0.30 for the quarter, an increase of 11% over the pro-forma E.P.S. of $0.27 reported for the first quarter of 2002. Free cash flow for the first quarter was approximately $30 million.
Commenting on the quarter Douglas Berthiaume, Chairman, President and Chief Executive Officer, said, "Overall our results reflect cautious spending by our pharmaceutical and life science customers and relatively stronger demand from our industrial customers. Sales growth by product line for the quarter was in line with our expectations. Additionally, we are pleased to report on the accelerated completion of our $200 million stock buy-back program and the successful integration of the recently acquired rheometry instrument product line within our TA Instruments division.
Lastly, at this year's ASMS conference in June, we plan to introduce a new triple quadrupole mass spectrometry system designed to meet the performance requirements of researchers in drug development. Our production plan anticipates shipments in late 2003."
The Company reported certain unusual charges in the first quarter, as explained in the accompanying financial schedules. These consisted of restructuring charges associated with the combination of the Company's field organizations, the divestiture of the Company's inorganic mass spectrometry business, the acquisition of the rheometry product line from Rheometrics Scientific, Inc. and charges related to on-going legal matters.
In addition to the results presented in accordance with Generally Accepted Accounting Principles (GAAP), the Company believes it is appropriate to provide "pro-forma" information that adjusts results to exclude unusual items such as non-operational, non-cash charges and benefits, and one-time charges. Management uses such pro-forma information internally to evaluate the Company's performance and to manage its operations. The accompanying financial schedules contain a detailed presentation of both GAAP and pro-forma results for the first quarter ended March 31, 2003.
As communicated in a prior press release, Waters Corporation will webcast its first quarter 2003 financial results conference call this morning, April 22, 2003, at 8:30 a.m. eastern time. To listen to the call, connect to www.waters.info , choose Investor Relations and click on the Live Webcast. A replay of the call will be available from today through April 28, 2003, similarly by webcast, and also by phone at 402-530-7669.
Waters Corporation holds worldwide leading positions in three complementary analytical technologies - high performance liquid chromatography (HPLC), mass spectrometry (MS) and thermal analysis (TA). These markets account for $4.4 billion of the overall $20 billion analytical instrument market.
This release contains "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward looking statements. Without limiting the foregoing, the words, "believes", "anticipates", "plans", "expects", "intends", "appears", "estimates", "projects", and similar expressions are intended to identify forward looking statements. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements within this release for a variety of reasons including and without limitation: loss of market share through competition, introduction of competing products by other companies, pressures on prices from competitors and/or customers, regulatory obstacles to new product introductions, lack of acceptance of new products, changes in the demands of the Company's healthcare and pharmaceutical company customers, changes in the healthcare market and the pharmaceutical industry, changes in distribution of the Company's products, the short-term effect on sales and expenses as a result of the formerly announced combination of the Waters and Micromass sales, service and distribution organizations, and foreign exchange fluctuations. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Form 10-K for the year ended December 31, 2002, as filed with the Securities and Exchange Commission, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this press release and should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future.
Waters Corporation and Subsidiaries Consolidated Statements of Operations (In thousands, except per share data) (Unaudited) Three Months Ended March 31 2003 2002 Net sales 220,999 200,341 Cost of sales 94,211 84,634 Gross profit 126,788 115,707 Selling, general and administrative expenses 61,611 55,716 Research and development expenses 13,560 12,280 Purchased technology amortization 1,028 915 Litigation provisions (A) 1,500 2,800 Loss on disposal of business (B) 5,031 - Restructuring and other unusual charges (C) 1,214 - Operating income 42,844 43,996 Interest income, net 825 1,378 Income from operations before income taxes 43,669 45,374 Provision for income taxes 9,692 10,324 Income before cumulative effect of change in accounting principle 33,977 35,050 Cumulative effect of change in accounting principle, net of tax (D) - (4,506) Net income 33,977 30,544 Income per basic common share: Net income before cumulative effect of accounting principle change 0.27 0.27 Cumulative effect of change in accounting principle (D) - (0.03) Net income 0.27 0.23 Income per diluted common share: Net income before cumulative effect of accounting principle change 0.26 0.26 Cumulative effect of change in accounting principle (D) - (0.03) Net income 0.26 0.22 Weighted average number of basic common shares 126,308 131,029 Weighted average number of diluted common shares and equivalents 130,785 137,188 (A) Includes a $1.2 million provision for an ongoing environmental matter with the Commonwealth of Massachusetts. (B) Loss on disposal of the inorganic mass spectrometry product line. (C) Includes restructuring and other incremental costs incurred in relation to the Company's reorganization of the HPLC and mass spectrometry businesses, and restructuring charges relating to the acquisition of the rheology business of Rheometric Scientific, Inc. (D) Effect at January 1, 2002 of a change in accounting method for patent related costs. Waters Corporation and Subsidiaries Consolidated Statements of Operations (In thousands, except per share data) (Unaudited) Three Months Ended March 31 2003 2002 Reconciliation of income per diluted share, in accordance with generally accepted accounting principles, with pro-forma results: Income per diluted share before cumulative effect of change in accounting principle 0.26 0.26 Adjustment for litigation provisions, net of tax 1,155 2,044 Income per diluted share effect 0.01 0.01 Adjustment for restructuring and other unusual charges, net of tax 935 - Income per diluted share effect 0.01 - Loss on disposal of business, net of tax 3,522 - Income per diluted share effect 0.03 - Pro-forma income per diluted share: 0.30 0.27 The pro-forma income per diluted share presented above is used by the management of the Company to measure operating performance with prior periods and is not in accordance with generally accepted accounting principles (GAAP). The above reconciliation identifies those items management has excluded as non-operational activities or transactions. Management feels these transactions are not indicative of understanding the ongoing operations of the business or its future outlook. Waters Corporation and Subsidiaries Condensed Consolidated Balance Sheets (In thousands and unaudited) March 31, December 31, 2003 2002 Cash and cash equivalents 271,572 263,312 Restricted cash 48,997 49,944 Accounts receivable 197,489 196,273 Inventories 124,853 126,920 Other current assets 15,309 13,341 Total current assets 658,220 649,790 Property, plant and equipment, net 104,517 103,650 Other assets 276,604 255,478 Total assets 1,039,341 1,008,918 Notes payable and debt 96,057 2,665 Accounts payable and accrued expenses 319,038 315,521 Total current liabilities 415,095 318,186 Other long-term liabilities 24,855 25,422 Total liabilities 439,950 343,608 Total equity 599,391 665,310 Total liabilities and equity 1,039,341 1,008,918